21 related articles for article (PubMed ID: 8223918)
1. Pain, Motivation, Migraine, and the Microbiome: New Frontiers for Opioid Systems and Disease.
Parker KE; Sugiarto E; Taylor AMW; Pradhan AA; Al-Hasani R
Mol Pharmacol; 2020 Oct; 98(4):433-444. PubMed ID: 32958571
[TBL] [Abstract][Full Text] [Related]
2. Kappa opioids and the modulation of pain.
Kivell B; Prisinzano TE
Psychopharmacology (Berl); 2010 Jun; 210(2):109-19. PubMed ID: 20372880
[TBL] [Abstract][Full Text] [Related]
3. A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.
Wadenberg ML
CNS Drug Rev; 2003; 9(2):187-98. PubMed ID: 12847558
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
Ko MC; Butelman ER; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
[TBL] [Abstract][Full Text] [Related]
5. Endogenous opiates: 1993.
Olson GA; Olson RD; Kastin AJ
Peptides; 1994; 15(8):1513-56. PubMed ID: 7700854
[TBL] [Abstract][Full Text] [Related]
6. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse.
Horan PJ; de Costa BR; Rice K; Haaseth RC; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1993 Aug; 266(2):926-33. PubMed ID: 8394923
[TBL] [Abstract][Full Text] [Related]
7. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
8. Differential antagonism of the rate-decreasing effects of kappa-opioid receptor agonists by naltrexone and norbinaltorphimine.
Powell KR; Holtzman SG
Eur J Pharmacol; 1999 Jul; 377(1):21-8. PubMed ID: 10448921
[TBL] [Abstract][Full Text] [Related]
9. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.
Horan P; Taylor J; Yamamura HI; Porreca F
J Pharmacol Exp Ther; 1992 Mar; 260(3):1237-43. PubMed ID: 1312164
[TBL] [Abstract][Full Text] [Related]
10. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
11. Lack of cross-tolerance between U69,593 and bremazocine suggests kappa-opioid receptor multiplicity in mice.
Horan PJ; Porreca F
Eur J Pharmacol; 1993 Aug; 239(1-3):93-8. PubMed ID: 8223918
[TBL] [Abstract][Full Text] [Related]
12. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties.
Dortch-Carnes J; Potter DE
CNS Drug Rev; 2005; 11(2):195-212. PubMed ID: 16007240
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
